A Phase IIa Randomized, Double-Blinded, Controlled With GARDASIL™ Clinical Trial to Study the Tolerability and Immunogenicity of V505 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like-Particle [VLP] Vaccine) in Healthy 16- to 26-Year- Old Women

Merck & Co., Inc.0 sites511 target enrollmentJanuary 27, 2017

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Not specified
Sponsor: Merck & Co., Inc.
Enrollment: 511
Status: Active, not recruiting
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

January 27, 2017

End Date

TBD

Last Updated

9 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

Female

Investigators

Sponsor

Merck & Co., Inc.

Eligibility Criteria

Inclusion Criteria

•For items with an asterisk (\*), if the subject does not meet these inclusion criteria, the Day 1 visit may be rescheduled for a time when these criteria can be met.
•1\. Subject is female, between the ages of 16 years and 0 days and 26 years and 364 days on the day of randomization.
•2\. Subject has never had Pap testing or has only had normal Pap test results (no abnormal result of ASC\-US or worse).
•3\. Subject fully understands study procedures, alternative treatments available, the risks involved with the study, and voluntarily agrees to participate by giving written informed consent.
•4\. Subject is able to read, understand, and complete the vaccination report card.
•5\. Subject is judged to be in good physical health on the basis of medical history, physical examination, and laboratory results.
•6\. Subject has had 0 to 4 male and/or female sexual partners at the time of enrollment. Male partner is defined as someone with whom the subject has penile penetrative sexual intercourse. Female partner is defined as someone who has contacted, either by penetrative (with fingers or other objects) or non\-penetrative means, the subject’s genitalia during sexual activity.
•7\. \*Subject has refrained from douching/vaginal cleansing and using vaginal medications or preparations for 2 calendar days prior to the Day 1 visit. Subject agrees to refrain from these activities for 2 calendar days prior to any future visit that includes collection of study specimens (cervical/genital swabs, Pap test, or
•biopsy/definitive therapy tissue).
•8\. \*Subject has refrained from sexual activity (including anal, vaginal, or genital/genital contact whether same sex or opposite sex) for 2 calendar days prior to the Day 1 visit. Subject agrees to refrain from these sexual activities for 2 calendar days prior to any future visit that includes collection of study specimens (cervical/genital swabs, Pap test, or biopsy/definitive therapy tissue).

Exclusion Criteria

•For items with an asterisk (\*), if the subject meets these exclusion criteria, the Day 1 visit may be rescheduled for a time when these criteria are not met.
•1\. Subject has a history of an abnormal cervical biopsy result (showing cervical intraepithelial neoplasia \[CIN] or worse).
•2\. Subject has a history of a positive test for HPV.
•3\. Subject is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use.
•4\. Subject has a history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension or shock) that required medical intervention.
•5\. Subject has known allergy to any vaccine component, including aluminum, yeast, ISCOMATRIX™ or BENZONASE™ (nuclease, Nycomed™ \[used to remove residual nucleic acids from this and other vaccines]). For the purpose of this exclusion criterion, an allergy to vaccine components is defined as an allergic reaction that met the criteria for serious adverse experiences defined in Section 3\.4\.
•6\. Subject is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition.
•7\. Subject has had a splenectomy.
•8\. Subject is receiving or has received in the year prior to enrollment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (Arava™), TNF\-?antagonists, monocolonal antibody therapies (including rituximab \[Rituxan™]), intravenous gamma globulin (IVIG), antilymphocyte sera, or other therapy known to interfere with the immune response. With regard to systemic corticosteroids, a subject will be excluded if she is currently receiving steroid therapy, has recently (defined as within 2 weeks of enrollment) received such therapy, or has received 2 or more courses of high dose corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to enrollment. Subjects using inhaled, nasal, or topical corticosteroids are considered eligible for the study.
•9\. Subject has received any immune globulin product (including RhoGAM™ \[Ortho\-Clinical Diagnostics]) or blood\-derived product within the 3 months prior to the Day 1 vaccination, or plans to receive any such product during Day 1 through Month 7 of the study.